DGX

Over the past six months (April - October 2026), Quest Diagnostics' stock (DGX) increased by 27.6% over the past year, with a significant daily move of +8.6% on July 23, 2026. On that date, the company reported strong fiscal Q2 2026 results, exceeding earnings expectations with adjusted diluted EPS of $3.12 and a 10.2% increase in revenue to $3.04 billion, leading to raised full-year 2026 guidance. In September 2026, Quest Diagnostics announced a major integration with Apple Health, allowing users to order and receive lab test results directly through the app, expected to boost its direct-to-consumer business. Other recent news includes studies on colorectal cancer trials and tick-borne pathogens. SEC filings from October 2026 indicate a $1.2 million target stock award for an executive's retirement and a director deferring cash pay for stock-linked units. Insider selling of $8.32 million worth of stock was reported over the past three months. Proposed reductions in Medicare reimbursement rates starting in 2027 could potentially impact future earnings.